ChartRow logo
Data provided bySource: Twelve Data
GKOS
$245.72-0.13%
as of close, Nov 13, 2026
☾ AH $245.72 -0.13%
PeersSNNPODDGMEDZBHPENSTE
Share this page

GKOS — Glaukos Corporation price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in GKOS be worth today? →
GKOS returns: By year · By month · By week · Trailing

Price data

Price
$245.72
YTD price return
+117.62%
YTD total return
+117.62%
Market cap
14.5B
Enterprise value
14.5B
Shares outstanding
59.2M
52W low
$87.32
52W high
$255.19
From 52W high
-3.71%
From 52W low
+181.40%
52W range
94%$87.32–$255
Beta
0.75

Volume

Rel volume
0.33×
30D volume
1.6M
30D $ vol
344.5M

Insider trading

Insider net 1W
none
Insider net 1M
−$11.3M
Insider net 3M
−$15.0M
Insider net 1Y
−$78.3M

Form 4 transactions by trade date, as filed; latest on file 2026-11-04.

Fundamentals

Sales (ttm)
690.3M
Sales/share
$11.66
EPS (ttm)
-$2.88
FCF (ttm)
36M
FCF/share
$0.61
Book value/share
$12.12
Net margin
-24.60%
ROE
-23.67%
ROA
-17.33%
Current ratio
4.57

Growth (CAGR, ttm) · 10Y

Sales
+46.97%+31.49%+18.62%+21.14%
FCF
n/an/an/a+25.06%
Shares
+3.07%+6.65%+4.77%+5.84%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+42.60%+23.30%+13.22%+14.45%
FCF/share
n/an/an/a+18.16%
Book value/share
-9.57%+7.37%-1.12%+13.94%
Price
+167.82%+56.99%+37.10%+21.86%
Total return
+167.82%+56.99%+37.10%+21.86%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-85.2×
Fwd P/E
175.5×
P/S (ttm)
21.1×
P/B (mrq)
20.3×
P/FCF (ttm)
403.8×
EV/Sales (ttm)
21.0×
FCF yield (ttm)
0.25%
Buyback yield (realized, 1y)
-3.07%
Shareholder yield (realized, 1y)
-3.07%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
97th
P/B
100th
P/FCF
100th

Bar = where today’s multiple sits in GKOS’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
-0.13%
5D
+9.50%
1M
+48.47%
3M
+29.70%
YTD
+117.62%
1Y
+167.64%
5Y
+384.65%
1D
-0.13%
5D
+9.50%
1M
+48.47%
3M
+29.70%
YTD
+117.62%
1Y
+167.64%
5Y
+384.65%

Fundamentals#

Revenue

5Y CAGR +17.7%10Y CAGR +21.6%YoY +58.0%
$690.3M TTM$211M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$176.2M TTM$828K Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y n/mYoY n/m
−$2.88 TTM$0.03 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
$36M TTM$36.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $47.7M, capex −$11.7M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $38.6M, capex −$2.1M

Shares (diluted)

5Y +28.5%10Y +227.3%YoY +6.6%
58.9M TTM61.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$169.8M TTM$2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full GKOS financials →

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release drug delivery systems, and bio-activated therapies designed to address chronic eye disease across multiple stages of care. The company serves ophthalmologists, surgeons, and healthcare providers with solutions intended to improve treatment options in both surgical and pharmaceutical settings. Glaukos Corp. is a specialized participant in the eye care market, combining medical devices and medicines to support procedures and therapies used in glaucoma management and corneal health.

Aliso Viejo, CA·995 employees·Medical Devices·glaukos.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding GKOS#

15 of the 193 ETFs ChartRow carries live hold GKOS. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
VIOOVanguard S&P Small-Cap 600 ETF0.6%
IWOiShares Russell 2000 Growth ETF0.5%
IJRiShares Core S&P Small-Cap ETF0.4%
VTWOVanguard Russell 2000 ETF0.3%
IWMiShares Russell 2000 ETF0.2%
VBKVanguard Small-Cap Growth ETF0.2%
VHTVanguard Health Care ETF0.1%
VXFVanguard Extended Market ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%